Jun 13, 2022 / 09:00PM GMT
Keyur Parekh - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Good afternoon, good evening, and thank you all for joining us. My name is Keyur Parekh. And hopefully, you can all hear me okay. Deborah, Kim, hopefully, you guys -- both of you can hear me okay. Brilliant. So thank you all for joining. As I said, my name is Keyur Parekh, and I cover GlaxoSmithKline for Goldman Sachs. I'm truly sorry, I'm not there in person this afternoon. But Deborah, Kim, thank you very much for joining us.
So by way of introduction, Deborah is the CEO of ViiV, which is the HIV business for GlaxoSmithKline; and Kim is the Head of R&D kind of for ViiV. So Deborah, before we go into the Q&A session, just wondering if you want to kind of give us some important comments, your thoughts on how you see the landscape for HIV therapeutics, and then we'll go into some question and answers before we turn it over to the audience questions. But please kick us off.
Deborah Jayne Waterhouse - GSK plc - CEO of ViiV Healthcare
Great. So it's an exciting time for
GSK plc at Goldman Sachs Global Healthcare Conference Transcript
Feb 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers